Marqibo ® (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine
Reads0
Chats0
TLDR
VSLI was developed to increase the circulation time, optimize delivery to target tissues and facilitate dose intensification without increasing toxicity, and in xenograft studies in mice, VSLI had a higher maximum tolerated dose, superior antitumor activity and delivered higher amounts of active drug totarget tissues compared to standard VCR.Abstract:
Vincristine (VCR) is a mainstay of treatment of hematologic malignancies and solid tumors due to its well-defined mechanism of action, demonstrated anticancer activity and its ability to be combined with other agents. VCR is an M-phase cell cycle-specific anticancer drug with activity that is concentration and exposure duration dependent. The pharmacokinetic profile of standard VCR is described by a bi-exponential elimination pattern with a very fast initial distribution half-life followed by a longer elimination half-life. VCR also has a large volume of distribution, suggesting diffuse distribution and tissue binding. These properties may limit optimal drug exposure and delivery to target tissues as well as clinical utility as a single agent or as an effective component of multi-agent regimens. Vincristine sulfate liposome injection (VSLI), Marqibo®, is a sphingomyelin and cholesterol-based nanoparticle formulation of VCR that was designed to overcome the dosing and pharmacokinetic limitations of standard VCR. VSLI was developed to increase the circulation time, optimize delivery to target tissues and facilitate dose intensification without increasing toxicity. In xenograft studies in mice, VSLI had a higher maximum tolerated dose, superior antitumor activity and delivered higher amounts of active drug to target tissues compared to standard VCR. VSLI recently received accelerated FDA approval for use in adults with advanced, relapsed and refractory Philadelphia chromosome-negative ALL and is in development for untreated adult ALL, pediatric ALL and untreated aggressive NHL. Here, we summarize the nonclinical data for VSLI that support its continued clinical development and recent approval for use in adult ALL.read more
Citations
More filters
Journal ArticleDOI
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
TL;DR: It is anticipated that precisely engineered nanoparticles will emerge as the next-generation platform for cancer therapy and many other biomedical applications.
Journal ArticleDOI
Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery
TL;DR: Recent developments with multifunctional and stimuli-sensitive NDDSs and their therapeutic potential for diseases including cancer, cardiovascular diseases and infectious diseases are highlighted.
Journal ArticleDOI
Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
TL;DR: This review offers a detailed description of different cytotoxic drug carriers, such as liposomes, carbon nanotubes, dendrimers, polymeric micelles,polymeric conjugates and polymeric nanoparticles, in passive and active targeted cancer therapy, by enhancing the permeability and retention or by the functionalization of the surface of the carriers.
Journal ArticleDOI
New Developments in Liposomal Drug Delivery.
TL;DR: Bhushan S. Pattni,† Vladimir V. Chupin,‡ and Vladimir P. Torchilin study the role of phosphorous in the biosynthesis of Membrane Proteins and found that phosphorous binds to polypeptide A in a manner similar to that of polymethine.
Journal ArticleDOI
Nanoparticles in the clinic.
TL;DR: This work highlights the diversity of nanoparticle types, the key advantages these systems have over their free drug counterparts, and their overall potential in influencing clinical care, and focuses on current clinical trials for nanoparticle formulations that have yet to be clinically approved.
References
More filters
Journal ArticleDOI
Acute lymphoblastic leukaemia
TL;DR: Advances in understanding of the pathobiology of acute lymphoblastic leukaemia, fuelled by emerging molecular technologies, suggest that drugs specifically targeting the genetic defects of leukaemic cells could revolutionise management of this disease.
Journal Article
Optimizing Liposomes for Delivery of Chemotherapeutic Agents to Solid Tumors
TL;DR: There are many potential barriers to the effective delivery of a drug in its active form to solid tumors, and small-molecule chemotherapeutic agents have a large volume of distribution on i.v. administration.
Acute Lymphoblastic Leukaemia
TL;DR: This chapter is dedicated to the preparation of ALL samples for cytogenetic and FISH analysis, with emphasis on the modifications to standard protocols which may be used to improve their quality.
Journal ArticleDOI
Results of Treatment With Hyper-CVAD, a Dose-Intensive Regimen, in Adult Acute Lymphocytic Leukemia
Hagop M Kantarjian,Susan O'Brien,Terry L. Smith,Jorge E. Cortes,Francis Giles,Miloslav Beran,Sherry Pierce,Yang O. Huh,Michael Andreeff,Charles A. Koller,Chul S. Ha,Michael J. Keating,Sharon B. Murphy,Emil J. Freireich +13 more
TL;DR: Hyper-CVAD therapy is superior to previous regimens and should be compared with established regimens in adult ALL, and a smaller percentage had more than 5% day 14 blasts and better survival.
Journal Article
The Vinca Alkaloids: A New Class of Oncolytic Agents
TL;DR: A phytochemical investigation of the plant Vinca rosea Linn has demonstrated that a number of alkaloidal substances can be obtained with antitumor activity, including vinblastine, vincristine, and vinrosidine, which are capable of prolonging and/or “curing” mice of the P-1534 leukemia.
Related Papers (5)
Liposomal drug delivery systems: from concept to clinical applications.
A New Concept for Macromolecular Therapeutics in Cancer Chemotherapy: Mechanism of Tumoritropic Accumulation of Proteins and the Antitumor Agent Smancs
Yasuhiro Matsumura,Hiroshi Maeda +1 more